西格列汀或格列美脲联合地特胰岛素治疗2型糖尿病的临床研究  

Clinical Research on Sitagliptin or Glimepiride Combined with Insulin Detemir in Treatment of Type 2 Diabetes

作　　者：周珈莉[1] 张建伟[1] 陈晓蕾[1] 

机构地区：[1]昆明市第一人民医院内分泌科,云南昆明650011

出　　处：《糖尿病新世界》2017年第5期90-92,共3页Diabetes New World Magazine

摘　　要：目的比较西格列汀联合地特胰岛素与格列美脲联合地特胰岛素治疗T2DM的疗效。方法将80例口服降糖药OAD血糖控制不佳的T2DM患者随机分为西格列汀联合地特胰岛素组(观察组)和格列美脲联合地特胰岛素组(对照组),治疗12周,观察FPG、2 hPG、HbA1c、BMI等指标及低血糖发生情况、胰岛素用量。结果治疗后两组FPG、2 hPG、HbA1c均较治疗前下降(P<0.05);观察组与对照组HbA1c达标率分别为87.5%、85.0%(P>0.05),但观察组胰岛素用量比对照组减少了10.4%,同时低血糖发生率低,BMI得到控制。结论西格列汀联合地特胰岛素治疗在有效控制血糖和体重同时,减少低血糖事件,同等HbA1c达标情况下,所用的胰岛素剂量更少。Objective To compare the curative effect of sitagliptin or glimepiride combined with Insulin detemir in treat- ment of type 2 diabetes. Methods 80 cases of T2DM patients taking the hypoglycemic orally but with bad blood glucose control effect were randomly divided into two groups, the observation group adopted the sitagliptin and insulin detemir, while the control group adopted the glimepiride combined with insulin detemir, after 12-week treatment, the FPG, 2hPG, HbAlc, BMI and occurrence of low blood glucose and insulin dose of the two groups were observed. Results The FPG, 2hPG, HbAle of the two groups decreased compared with those before treatment（P〈0.05）, and the standard-reaching rate of HbAle of the two groups was respectively 87.5% and 85.0%（P〉0.05）, but the insulin dose in the observation group de- creased by 10.4% compared with that in the control group, at the same time, the incidence rate of low blood glucose was low and BMI was controlled. Condusion Sitagliptin and insulin detemir treatment can effectively control the blood glucose and weight and reduce the low blood glucose events, which can reach the same HbAlc standard-reaching rate with less in- sulin dose.

关 键 词：西格列汀 地特胰岛素 格列美脲2型糖尿病 

分 类 号：R969[医药卫生—药理学]